Lenalidomid Fresenius Kabi (Lenalidomide)

Lenalidomide is indicated for several hematologic malignancies, targeting abnormal plasma cells and dysplastic bone‑marrow clones.

• Multiple myeloma: improves progression‑free survival and overall response rates in adult patients.
• Myelodysplastic syndromes with del(5q): reduces transfusion dependence and induces cytogenetic remission.
• Mantle cell lymphoma: used in combination regimens to achieve disease control in relapsed or refractory cases.

• Lenalidomide binds to the cereblon component of the CRL4 E3 ubiquitin ligase complex, altering substrate specificity and promoting ubiquitination and proteasomal degradation of transcription factors Ikaros (IKZF1) and Aiolos (IKZF3). This results in modulation of cytokine production, enhanced immune‑mediated tumor cell killing, anti‑angiogenic activity, and direct inhibition of malignant cell proliferation.

Lenalidomide may cause a range of adverse reactions, which are classified by frequency and severity.

Common Side Effects

• Fatigue: persistent tiredness affecting daily activities.
• Diarrhea: loose stools that may require hydration.
• Rash: mild to moderate skin eruptions.
• Constipation: reduced bowel movements.
• Nausea: feeling of sickness often without vomiting.
• Peripheral edema: swelling of extremities.

Serious or Rare Side Effects

• Thromboembolic events: deep‑vein thrombosis or pulmonary embolism.
• Severe neutropenia: markedly low neutrophil counts increasing infection risk.
• Secondary primary malignancies: emergence of new cancers unrelated to the original disease.

Lenalidomide requires careful monitoring and specific safety measures before and during therapy.

• Pregnancy: contraindicated (Category X); avoid use in pregnant women and ensure effective contraception.
• Thrombosis risk: assess for prior clotting events and consider prophylactic anticoagulation.
• Renal impairment: adjust monitoring and dosing in patients with reduced kidney function.
• Hepatic dysfunction: evaluate liver enzymes and monitor for hepatotoxicity.
• Infections: monitor for signs of infection, especially in neutropenic patients.
• Store at ambient temperature: keep below 25 °C, in the original container, protected from moisture and direct sunlight.

Lenalidomide can interact with several drug classes, influencing efficacy or safety.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce lenalidomide exposure.
• Anticoagulants (e.g., warfarin, direct oral anticoagulants): increased risk of bleeding when combined with lenalidomide‑related thrombocytopenia.

Moderate Interactions (Monitor Closely)

• P-glycoprotein inhibitors (e.g., amiodarone, verapamil): may modestly increase plasma levels.
• Immunosuppressants (e.g., cyclosporine, tacrolimus): heightened risk of infection and hematologic toxicity.
• Vaccines: live attenuated vaccines should be avoided due to immunomodulatory effects.